Free Trial

Bioventix (BVXP) Competitors

Bioventix logo
GBX 2,950 -50.00 (-1.67%)
As of 02/21/2025 11:39 AM Eastern

BVXP vs. SLN, PRTC, OXB, HZD, FARN, VRP, ARIX, AVCT, 4BB, and CIR

Should you be buying Bioventix stock or one of its competitors? The main competitors of Bioventix include Silence Therapeutics (SLN), PureTech Health (PRTC), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Avacta Group (AVCT), 4basebio (4BB), and Circassia Group (CIR). These companies are all part of the "biotechnology" industry.

Bioventix vs.

Silence Therapeutics (LON:SLN) and Bioventix (LON:BVXP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Silence Therapeutics received 111 more outperform votes than Bioventix when rated by MarketBeat users. Likewise, 68.81% of users gave Silence Therapeutics an outperform vote while only 52.87% of users gave Bioventix an outperform vote.

CompanyUnderperformOutperform
Silence TherapeuticsOutperform Votes
203
68.81%
Underperform Votes
92
31.19%
BioventixOutperform Votes
92
52.87%
Underperform Votes
82
47.13%

Bioventix has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silence Therapeutics£11.35M0.00N/A-£48.60N/A
Bioventix£13.65M11.32£8.12M£154.6219.08

In the previous week, Silence Therapeutics' average media sentiment score of 0.00 equaled Bioventix'saverage media sentiment score.

Company Overall Sentiment
Silence Therapeutics Neutral
Bioventix Neutral

62.3% of Bioventix shares are owned by institutional investors. 8.0% of Bioventix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Bioventix has a net margin of 59.51% compared to Silence Therapeutics' net margin of 0.00%. Bioventix's return on equity of 69.09% beat Silence Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Silence TherapeuticsN/A N/A N/A
Bioventix 59.51%69.09%54.07%

Summary

Bioventix beats Silence Therapeutics on 8 of the 10 factors compared between the two stocks.

Get Bioventix News Delivered to You Automatically

Sign up to receive the latest news and ratings for BVXP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BVXP vs. The Competition

MetricBioventixBiotechnology IndustryMedical SectorLON Exchange
Market Cap£154.47M£118.00M£5.84B£2.64B
Dividend Yield5.48%3.69%4.75%4.98%
P/E Ratio19.083.2026.15162.45
Price / Sales11.324,826.69435.33313,812.88
Price / Cash30.8913.0138.0128.15
Price / Book12.8347.077.645.16
Net Income£8.12M-£87.82M£3.19B£5.75B
7 Day Performance1.72%0.38%-2.11%-0.99%
1 Month Performance-7.52%3.67%-0.49%-0.81%
1 Year Performance-41.76%99.17%16.44%39.56%

Bioventix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BVXP
Bioventix
N/AGBX 2,950
-1.7%
N/A-41.7%£154.47M£13.65M19.0812
SLN
Silence Therapeutics
N/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading Volume
PRTC
PureTech Health
2.0058 of 5 stars
GBX 145.80
-0.1%
GBX 455
+212.1%
-24.1%£437.96M£521,320.79-5.98300News Coverage
OXB
Oxford Biomedica
2.541 of 5 stars
GBX 385
-1.0%
GBX 433.33
+12.6%
+102.0%£409.26M£98.31M-2.86891News Coverage
HZD
Horizon Discovery Group plc (HZD.L)
N/AN/AN/AN/A£302.98M£54.63M-33.55416
FARN
Faron Pharmaceuticals Oy
N/AGBX 173.90
+3.8%
N/A+32.3%£233.46MN/A-4.6534
VRP
Verona Pharma plc (VRP.L)
N/AN/AN/AN/A£228MN/A-1.6822Gap Up
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
AVCT
Avacta Group
N/AGBX 40.20
-3.4%
N/A-53.9%£152.72M£26.29M-5.17120Negative News
Gap Up
High Trading Volume
4BB
4basebio
N/AGBX 1,120
flat
N/A+52.3%£143.47M£311,000.00-1,435.90101
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap Down

Related Companies and Tools


This page (LON:BVXP) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners